Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Oct
15
Today In Oncology
New AACI President-Elect Selected; Two Cancer Center Leaders Join Board
10-Year Incidence of Second Cancers in HPV Oropharyngeal Cancer
Individuals With Rare Cancers Present Distinct Diagnosis Patterns; Many Experience Treatment Delays
Combination Therapies for Diffuse Large B-Cell Lymphoma 5-Year Outcomes of POLARIX Trial
Chemotherapy-Free Regimen vs Standard Immunochemotherapy in Mantle Cell Lymphoma in Older Patients
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo